Nippon Chemiphar : Chemiphar announced second quarter business summary FY2022.

（TSE 4539）

FY2022 Second Quarter Business Summary

(Year Ending March 31, 2023)

Sales, Income

									(¥mn)
			FY2021				FY2022
		2Q	Distrib.	Full Year	2Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)	(Forecast)	Rate (%)
Net sales	15,575	100.0	32,506	16,237	100.0	4.3	35,000	46.4
Pharmaceuticals	15,115	97.0	31,501	15,798	97.3	4.5	―	―
Generics, proprietary products
and new drugs	13,468	86.5	28,037	13,695	84.3	1.7	29,000	47.2
Diagnostics	996	6.4	2,163	1,239	7.6	24.3	3,120	39.7
Others		460	3.0	1,004	439	2.7	(4.5)	―	―
Cost of sales		11,265	72.3	23,432	11,976	73.8	6.3	―	―
SG&A expenses	4,103	26.3	8,248	4,093	25.2	(0.2)	―	―
R&D expenses		1,188	7.6	2,392	1,022	6.3	(14.0)	3,000	34.1
Operating profit		206	1.3	825	167	1.0	(18.8)	300	55.8
Ordinary profit	258	1.7	1,022	752	4.6	190.7	500	150.5
Net profit attributable to
owners of parent		228	1.5	700	896	5.5	291.6	550	163.0

1

Pharmaceutical Sales

Generics, Proprietary Products and New Drugs						(¥mn)
			FY2021				FY2022
		2Q	Distrib.	Full Year	2Q	Distrib.	YOY	Full Year	Progress
		Amount	(%)	Amount	Amount	(%)	(%)	(Forecast)	Rate (%)
Total	13,468	100.0	28,037	13,695	100.0	1.7	29,000	47.2
Generics	12,581	93.4	26,283	13,010	95.0	3.4	27,440	47.4
	To medical institutions	12,010		25,043	12,423		3.4	26,600	46.7
	To other makers*	571		1,239	586		2.6	840	69.9
Proprietary products	887	6.6	1,754	685	5.0	(22.7)	1,560	43.9
	Uralyt	317		623	291		(8.3)	580	50.2
	Others	569		1,131	394		(30.8)	980	40.2
* Includes exports.

Chemiphar, ODM Generics										(¥mn)
				FY2021					FY2022		Progress
			2Q	Distrib.	Full Year		2Q	Distrib.	YOY	Full Year
			Amount	(%)	Amount		Amount	(%)	(%)	(Forecast)	Rate (%)
Total		12,984	100.0	27,139		13,627	100.0	5.0	28,450	47.9
Generics		12,581	96.9	26,283		13,010	95.5	3.4	27,440	47.4
Generics (ODM)		402	3.1	856	617	4.5	53.3	1,010	61.1

2

Sales Distribution

By Launch Year						(¥mn)
		FY2021		FY2022
		2Q	Distrib.	2Q	Distrib.	YOY
		Amount	(%)	Amount	(%)	(%)
FY2015 and before		10,208	81.1	10,391	79.9	1.8
FY2016		285	2.3	310	2.4	8.8
FY2017		767	6.1	792	6.1	3.3
FY2018		388	3.1	413	3.2	6.4
FY2019		66	0.5	69	0.5	4.7
FY2020		678	5.4	688	5.3	1.6
FY2021	187	1.5	224	1.7	19.8
FY2022		―	―	118	0.9	―
Total		12,581	100.0	13,010	100.0	3.4

By Main Therapeutic Categories		(%)
	FY2021	FY2022
	2Q	2Q
	Distrib.	Distrib.
Cardiovascular and respiratory drugs	28.2	27.6
Digestive organ drugs	15.9	17.4
Agents affecting metabolism	15.0	15.0
Drugs for nervous system, sensory organs	13.3	13.3
Antibiotics and chemotherapeutic drugs	6.3	4.6
Antineoplastic agents	2.4	1.9
Others	18.9	20.2

3

Balance Sheet, per Share Information

Balance Sheet Data				(¥mn)
		March 31, 2022	September 30, 2022
		Amount	Amount	Change
Total assets		49,453	50,658	1,204
Net assets	18,501	18,974	473
Owned capital	18,484	18,957	473
Capital-to-asset ratio (%)		37.4	37.4	0.0
Current assets		33,495	35,081	1,586
Current liabilities	16,750	15,860	(889)
Current ratio (x)		2.00	2.21	0.21

Per Share Information						(¥)
			FY2021		FY2022
			2Q	Full Year	2Q		Full Year
			Amount	Amount	Amount	YOY	(Forecast)
Earnings per share		63.56	194.33	248.43	184.87	152.50
			Sept. 30,	March 31,	Sept. 30,		Full Year
			2021	2022	2022		(Forecast)
Book value per share		5,037.24	5,119.99	5,252.48	215.24	―
Dividends per share			―	50.00	―	―	50.00
Dividend payout ratio (%)		―	25.7	―	―	32.8

4